NCT05116462 2025-06-26
Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3 Active not recruiting
Clinical Trials
10 trialsNCT05549037 2025-02-19
PACIFIC15
Hunan Province Tumor Hospital
Phase 3 Recruiting
NCT06485557 2024-07-03
A Prospective Cohort Study of Neoadjuvant Chemotherapy Plus Sintillumab in the Treatment of Resectable NSCLC
Tang-Du Hospital
Phase 3 Not yet recruiting
NCT03802240 2023-11-27
Sintilimab ± IBI305 Plus Chemotherapy (Pemetrexed + Cisplatin) for EGFRm + Locally Advanced or Metastasis Non-Squamous NSCLC Patients After EGFR-TKI Treatment Failure
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3 Completed
NCT06031597 2023-09-13
Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy
Zhejiang Cancer Hospital
Phase 3 Unknown
NCT03150875 2023-02-28
A Study Comparing the Efficacy and Safety Between IBI308 and Docetaxel in Patients With Advanced or Metastatic NSCLC
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3 Completed
NCT03629925 2023-02-28
Sintilimab in Combination With Gemcitabine and Platinum-Based Chemotherapy as First-Line Therapy for Advanced or Metastatic Squamous NSCLC
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3 Completed
NCT03607539 2023-02-27
Efficacy and Safety Evaluation of Sintilimab in Patients With Advanced or Metastatic Non-squamous NSCLC
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3 Completed
NCT05429463 2022-12-14
neoSCORE â…¡
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 3 Recruiting
NCT05648071 2022-12-13
SPBPDC
Qianfoshan Hospital
Phase 3 Unknown